stockportfolio.pro
Stocks / BMY vs DHR
BMY vs DHR
Bristol-Myers Squibb Company and Danaher Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bristol-Myers Squibb Company (BMY) | Danaher Corporation (DHR) | |
|---|---|---|
| Market cap | $114.8B | $128.2B |
| Revenue (latest FY) | $48.19B | $24.57B |
| Net income (latest FY) | $7.05B | $3.61B |
| Revenue growth (5y CAGR) | 2.5% | 2.0% |
| Net margin | 14.6% | 14.7% |
| Return on equity | 38.2% | 6.9% |
| P/E ratio | 15.8 | 35.0 |
| Dividend yield | 4.4% | 0.9% |
| Profitable years (of last 10) | 8 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BMY — free Open DHR — freeFrequently asked questions
Which is bigger, BMY or DHR?
Danaher Corporation is larger by market capitalization — $128.2B versus $114.8B.
Which grows faster, BMY or DHR?
Over the last five fiscal years, Bristol-Myers Squibb Company grew revenue faster — 2.5%/yr versus 2.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.